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A lysosome-based mechanism of amino acid sensing by mTORC1 regulated by Rag GTPases has emerged.
In this issue of Cancer Cell, Thomas and colleagues propose a Golgi-based and Rag-independent mecha-
nism mediated by the Rab1A GTPase. Furthermore, Rab1A overexpression in colorectal cancers correlates
with mTORC1 activity and sensitivity to mTOR inhibitors.Working at the hospital in Abbiategrasso,
Italy in 1872, Camillo Golgi discovered the
‘‘black reaction’’ while attempting to find
new staining techniques to examine
neuron structure (Bentivoglio, 1998). This
stain provided the first clear view of an
intricate ‘‘internal reticular apparatus’’,
which was later named Golgi stain in hon-
or of its discoverer and future Nobel laure-
ate, and eventually led to the discovery of
the endomembrane system, including
the endoplasmic reticulum, Golgi, endo-
somes, and lysosomes. Golgi noticed,
however, that this apparatus was not
restricted to neurons, formed complex
intracellular networks, and was dynamic
particularly in secretory cells, where it
changed shape and location during
secretion. Based on these observations,
Golgi concluded that his reticular appa-
ratus must be of broad functional signifi-
cance and hypothesized a role for the
Golgi apparatus in ‘‘nutritive endocellular
pathways’’. Fast forward more than a
century, Thomas et al. (2014; in this
issue of Cancer Cell) uncover evidence
of a Golgi-based mechanism of nutrient
sensing, adding a twist in the rapidly
evolving saga of how amino acids activate
mTORC1.
Over the last two decades, the mTOR
kinase has emerged as a central
controller of cell growth that senses both
local nutrient availability such as amino
acid (AA) levels and systemic nutrient
availability through growth factor (GF)
signaling. A watershed moment in under-
standing how mTOR is activated was the
discovery that mTOR assembles into at
least two distinct multiprotein complexes,
called mTOR complex 1 (mTORC1) and 2
(mTORC2), and that mTORC1, which
contains the scaffolding protein Raptor,
is the main driver of cell growth (Laplante
and Sabatini, 2012). It soon became clear,however, that mTORC1 sensed GFs and
AAs by different mechanisms, but exactly
how mTORC1 sensed AAs remained a
black box until the discovery that the
Rag GTPases promotedmTORC1 activity
in response to AAs not by directly acti-
vating it, but by controlling its localization
(Kim et al., 2008; Sancak et al., 2008).
The Rag proteins are obligate hetero-
dimers of RagA/B with RagC/D that
localize to the lysosome (Figure 1, left).
In the presence of AAs, RagA/B is GTP
bound and RagC/D is GDP bound, and
this configuration recruits mTORC1 to
its activator, the Rheb GTPase, on the
lysosomal surface (Sancak et al., 2008).
This seminal discovery triggered a flurry
of studies that unveiled a mechanism
involving additional protein complexes,
including Ragulator, Folliculin, GATOR1,
GATOR2, and Sestrins that tightly regu-
late Rag activity (Bar-Peled and Sabatini,
2014; Chantranupong et al., 2014; Peng
et al., 2014). Although the exact identity
of the AA sensor remains mysterious,
the AA signal appears to emanate from
within the lysosome via the v-ATPase.
A recent study also sheds light on how
GF signaling integrates with AA sensing
to regulate mTORC1; GF signaling pro-
motes Rheb activity by removing its
negative regulator, the TSC complex,
from the lysosomal surface (Menon
et al., 2014). That AA-mTORC1 signaling
and GF-mTORC1 signaling converge on
lysosomes makes sense, because the
lysosome is a destination point for endo-
cytosis, autophagy, and, in some cells,
phagocytosis, and therefore is a good
candidate for a monitor of cellular meta-
bolic state.
Speculating, however, that nutrient
sensing is too important to be governed
only by the Rag pathway, Thomas et al.
(2014) looked for Rag-independentCancer Cell 26, Nregulators of AA signaling to mTORC1.
They first show in Saccharomyces cere-
visiae that deleting gtr1 or gtr2, which
encode orthologs of RagA/B and RagC/
D respectively, or inhibiting the biogen-
esis of the vacuole, the lysosome equiv-
alent, does not impair growth or TORC1
AA sensitivity. Focusing on GTPases,
the authors identify Ypt1 as being
uniquely required for AA-TORC1 sig-
naling in yeast. Ypt1 is the paralog of
Rab1, a Golgi GTPase that functions
in trafficking, although the authors
conclude this function is distinct.
A clue that Rab1 might regulate
mTORC1 in higher eukaryotes came
earlier from a mini-screen in cultured
Drosophila cells for GTPases that control
TORC1 activity (Li et al., 2010). Thomas
et al. (2014) go on to show that knocking
down Rab1A in mammalian cells inhibits
phosphorylation of the mTORC1 sub-
strate S6K, while ectopically expressing
Rab1A promotes S6K phosphorylation.
The authors also report that mTORC1
preferentially binds recombinant GTP-
bound Rab1A through Raptor, AA stimu-
lation increases Rab1A-GTP binding,
and the Rab1A-mTORC1 interaction re-
quires the prenylation modification that
tethers Rab1A to theGolgi. These findings
are further substantiated by co-localiza-
tion experiments placing Rab1A with
mTOR, Raptor, and Rheb at the Golgi
following AA stimulation. Another study
finds TSC complexes localize to the Golgi
in addition to lysosomes (Menon et al.,
2014). Aiming to distinguish the Rab1A
and Rag pathways, Thomas et al. (2014)
go on to show that RagB/RagC and
Rheb-dependent mTORC1 activation re-
quires Rab1A, whereas Rab1A-depen-
dent mTORC1 activation requires Rheb,
but only partially RagB/RagC. Finally, the
authors showRab1A knockdown disruptsovember 10, 2014 ª2014 Elsevier Inc. 601
Figure 1. Amino Acid Sensing by mTORC1 Occurs at Endomembranes and Is Regulated by
Multiple GTPases
mTORC1 controls cell growth in response to local amino acid availability and growth factor signaling. Over
the last few years a lysosome-based amino acid sensing mechanism has been described by which amino
acid sufficiency converts RagA/B to the GTP bound state and RagC/D to the GDP bound state, which re-
cruits mTORC1 to the lysosomal surface, where its activator, the Rheb GTPase, resides (left). Thomas
et al. (2014) now challenge the lysosome centric view of amino acid sensing by proposing an alternative
mechanism in which amino acids activate the Rab1A GTPase, which then recruits mTORC1 to the surface
of the Golgi (right). Whether these two mechanisms work in parallel as the authors propose or are part of
contiguous endomembrane-based mTORC1 regulatory system remains to be seen.
Cancer Cell
PreviewsmTORC1 localization to the Golgi, but not
to lysosomes. Based on these findings,
the authors contend that Rab1A functions
in an AA sensing pathway distinct from
the Rag pathway that is either redundant
or senses a different AA pool (Figure 1,
right).
The Golgi and lysosomes, however, are
not disconnected entities. For example,
lysosomal hydrolases modified with
mannose 6-phosphate (M6P) bind to
M6P receptors in the Golgi, triggering
their delivery on vesicles to late endo-
somes/lysosomes. Once the cargo is602 Cancer Cell 26, November 10, 2014 ª20delivered, vesicles recycle the M6P re-
ceptors back to the Golgi. Moreover,
exogenously obtained cholesterol traffics
on vesicles through the endosomal/lyso-
somal compartment en route to the Golgi,
ER, and plasmamembrane. Thus, an intri-
cate vesicle highway exists in which
cargos are shuttled around the endo-
membrane system via late endosomes/
lysosomes. An interesting possibility is
that, once activated at the lysosome,
mTORC1 takes advantage of these
traffic patterns to find its substrates. This
seems intuitive, because one function of14 Elsevier Inc.mTORC1 is to drive protein synthesis,
which occurs at rough endoplasmic
reticulum. This could also explain why
mTORC1 activity is sensitive to the activ-
ity of Rab and Arf family GTPases, which
regulate vesicle trafficking (Li et al.,
2010). Considering this possibility, the
findings by Thomas et al. (2014) are not
inconsistent (and may even be more
consistent) with Golgi-localized Rab1A
functioning in the same pathway and
possibly downstream of the lysosomal
Rag network (Figure 1). The follow-up
will certainly be interesting.
Thomas et al. (2014) also report that
Rab1A is highly expressed in human colo-
rectal cancers (CRCs), and this correlates
with mTORC1 activity, aggressiveness,
and poor prognosis. In CRC cell lines,
Rab1A overexpression correlates with
AA dependency and rapamycin sensitivity
and, on its own, can transform cells
(Thomas et al., 2014). Thus, Rab1A levels
might be an indicator of tumor sensitivity
to mTORC1 inhibitors. These findings
and previous work (Bar-Peled and Saba-
tini, 2014) clearly implicate deregulated
AA sensing in cancer. However, many
important questions remain unanswered.
For instance, what is the AA sensor and
what exactly is being sensed? Domultiple
AA sensing mechanisms exist and, if so,
why? Where does inactive mTORC1 go?
Where does mTORC1 phosphorylate its
substrates?
It took many years before the scienti-
fic community accepted that the Golgi
apparatus was not a staining artifact
(Bentivoglio, 1998). But in the ensuing
years, a cell biology revolution tran-
spired, culminating in unprecedented
advancements in understanding the en-
domembrane system. Yet even today,
the distinction between certain organ-
elles and the intervening trafficking pat-
terns remains murky. However, Camillo
Golgi seems to have anticipated that
this system was important for cellular
nourishment, and knowing now that
the nutrient-sensing mTORC1 pathway
might utilize multiple components of the
endomembrane system sets the stage
for an exciting (and complex) narrative
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In BRAF V600Emelanoma patients, RAF inhibitor treatment causes aMEK-inhibitor-sensitive, RAF-inhibitor-
resistant adaptive reactivation of ERK signaling. In clinical trials combining MEK and RAF inhibitors, thera-
peutic efficacy was modestly enhanced, suggesting the utility of inhibiting feedback-reactivated pathways.
Strategies for optimally inhibiting ERK signaling should be explored.The RAS/RAF/MEK/ERK pathway is dys-
regulated in almost all melanomas, mostly
due to activating mutations of BRAF or
NRAS or genetic changes causing loss
of NF1 function. Inhibitors of this pathway
have attracted a great deal of interest as
therapeutics. Potent (>80%) inhibition of
ERK signaling is required for significant
antitumor activity (Bollag et al., 2010).
MEK inhibitors have only modest clinical
activity in these patients (Flaherty et al.,
2012), perhaps because MEK inhibitors
suppress ERK signaling in both tumor
and normal cells; thus, on-target toxicities
limit the doses that can be administered
safely. This is not the case for RAF inhibi-
tors. They selectively inhibit ERK signaling
inmelanomas that express themost com-
mon RAF mutations (BRAF V600E/K),
whereas they induce ERK signaling in
normal and other tumor cells. This para-doxical activation of ERK is due to trans-
activation of wild-type RAF dimers when
one protomer of the dimer is bound to
drug (Poulikakos et al., 2010). In most
melanomas, BRAF V600E exists as
a monomer and is inhibited potently by
drug (Poulikakos et al., 2011).
Tumor- and mutation-specific inhibition
of ERK signaling by RAF inhibitors ex-
plains their broad therapeutic index. The
two Food and Drug Administration (FDA)-
approved RAF inhibitors—vemurafenib
anddabrafenib—havehigh response rates
in BRAF-mutated melanomas (approxi-
mately 50%), and vemurafenib improves
patient survival (Chapman et al., 2011;
Hauschild et al., 2012). However, anti-
tumor responses are usually temporary
and rarely complete. Treatment is also
complicated by toxicities attributable to
ERK activation in skin, including hypertro-phic skin changes and induction of kera-
toacanthomas and cutaneous squamous
cell carcinomas.
Inhibition of ERK signaling in BRAF
mutant tumors relieves ERK-dependent
feedback inhibition of receptor signaling
and of CRAF kinase activity. This results
in induction of RAS activation, formation
of RAF inhibitor-resistant, wild-type CRAF
dimers, and a rebound in ERK activation
that is sensitive to MEK inhibitors but
resistant to RAF inhibitors (Lito et al.,
2012). These results imply that the adap-
tive rebound in ERK signaling in tumors
exposed toRAF inhibitorsmay reduce their
clinical effectiveness. Addition of MEK in-
hibitors might therefore reduce the toxicity
(by antagonizing the paradoxical activation
of ERK in normal cells) and enhance the
effectiveness of RAF inhibitors (by further
inhibiting ERK in tumor cells). Two suchovember 10, 2014 ª2014 Elsevier Inc. 603
